Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627435 | 0.90 | CCR2 (0.50) | CCR2KCNH2SYKACACBHRH3 | |
| SCHEMBL13627267 | 0.88 | CCR2 (0.53) | CCR2KCNH2SYKHRH3MAPT | |
| SCHEMBL13627021 | 0.88 | CCR2 (0.54) | CCR2KCNH2SYKHRH3MAP3K12 | |
| SCHEMBL13627093 | 0.87 | CCR2 (0.57) | CCR2KCNH2SYKMAPTMAP3K12 | |
| SCHEMBL13627018 | 0.87 | CCR2 (0.57) | CCR2KCNH2SYKMAPTMAP3K12 | |
| SCHEMBL13627090 | 0.87 | CCR2 (0.68) | CCR2KCNH2HCRTR1HCRTR2SYK | |
| SCHEMBL13627266 | 0.86 | CCR2 (0.57) | CCR2KCNH2SYK | |
| SCHEMBL13627015 | 0.85 | CCR2 (0.55) | CCR2KCNH2SYKHRH3MAP3K12 | |
| SCHEMBL13627175 | 0.82 | CCR2 (0.61) | CCR2KCNH2HCRTR1HCRTR2SYK | |
| SCHEMBL4322305 | 0.81 | CCR2 (0.77) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | XUE CHU-BIAO | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286792-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | CCR2 1/4885KCNH2 2769/4885HCRTR1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.